Question 1

What is GHK-Cu?

Accepted Answer

GHK-Cu is a copper complex of a three-amino-acid peptide the body already makes for itself: the peptide is glycyl-L-histidyl-L-lysine, shortened to GHK, and the Cu is the copper it carries. It is not foreign to the body, and its level is not fixed. A 2020 paper describes GHK (glycyl-L-histidyl-L-lysine) as a naturally occurring peptide found in human serum with levels averaging 200 ng/ml at age 20 but declining to an average of 80 ng/ml by age 60. The same paper notes that the molecule has a very high affinity for copper and forms the chelate GHK-Cu. A chelate is a metal ion held by a molecule rather than floating free in solution. That pairing of a falling natural level with a visible job in skin is why it is sold as an anti-ageing ingredient. The wider category it belongs to is set out on the copper peptides page.

Question 2

Is GHK-Cu the same as copper tripeptide-1?

Accepted Answer

Yes, and copper tripeptide-1 is simply the cosmetic-ingredient name for the same molecule, one of several labels the literature uses for it. A 2026 sports medicine review writes it out as GHK-Cu (glycyl-L-histidyl-L-lysine copper). A 2026 scoping review writes GHK-Cu [copper peptide]. A 2026 skin-delivery paper calls it copper tripeptide-1 with PLA STAR particles, meaning the same tripeptide loaded onto a delivery particle. A 2014 study simply refers to the tripeptides such as Gly-His-Lys (GHK) and their copper complexes. The distinction that does matter is between the peptide and the complex. A 2012 review notes that GHK has high affinity for copper ions and easily forms a copper complex or GHK-Cu. The bare peptide and the copper-bound form are two different things built from the same three amino acids, and a product label rarely says which one is in the bottle. How GHK-Cu sits inside the wider copper peptide category is covered on the copper peptides page.

Question 3

Will GHK-Cu ever be FDA approved?

Accepted Answer

Nobody can answer that. What is on the record is the current position and the distance still to travel. GHK-Cu is not approved by the FDA for any medical use. According to a 2026 review of regenerative peptides, most of these therapies remain unapproved by the U.S. Food and Drug Administration (FDA). A 2026 ageing review adds that non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation. Approval needs trials, and one is running: Topical GHK-Cu Gel for Acute Skin Wound Healing is a Phase 2 study listed as RECRUITING. A second registry entry, the Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults, is marked NOT_YET_RECRUITING and measures blood levels rather than a clinical result. One Phase 2 skin trial is a long way from a licence. A 2026 review of injectable peptide therapy states that information regarding the indications, dosing, frequency, and duration of treatment remains unknown, and that is the gap which would have to close first.

Question 4

Does injectable GHK-Cu really work?

Accepted Answer

No study among the research behind this page has injected GHK-Cu into a person and measured anything. What exists is dosing into animals, and those results are real. A 2023 study dosed mice exposed to cigarette smoke. In CS-induced muscle dysfunction C57BL/6 mice, GHK-Cu treatment (0.2 and 2 mg/kg) reduces CS-induced muscle mass loss. That is a systemic dose in a living animal rather than a cream on skin. A 2026 study built a delivery system around the molecule, in which GHK-Cu serves as a stable copper source to provide a sustained release of Cu ions for cellular uptake. In a rabbit fascia defect model, this strategy effectively promoted collagen alignment and neovascularization. Fascia is the sheet of connective tissue under skin, and neovascularization means new blood vessels. Read both for what they are: each is an injury deliberately created in an animal and then treated. Neither tells you what an injection does in an intact adult, and no study among the research behind this page has asked that question. Those animal figures still do not fix an amount for a person, which is where the GHK-Cu dosage page begins.

Question 5

Does GHK-Cu speed up wound healing?

Accepted Answer

In animals and in cell models the answer is consistent, and in people the entire evidence is one trial that has not reported. A 2020 paper summarises the preclinical picture. GHK-Cu has been shown to promote skin remodeling, wound healing and regeneration, and has prominent antioxidant and anti-inflammatory effects in in vitro and in vivo studies. A 2018 review adds that the ability to improve tissue repair has been demonstrated for skin, lung connective tissue, boney tissue, liver, and stomach lining. Cell work points the same way. A 2026 study of a GHK-Cu formulation found that it promoted keratinocyte migration during wound healing assays, using a human skin cell line. Keratinocytes are the main cells of the skin surface, and their migration is how a wound closes in miniature. The human test is running now, and Topical GHK-Cu Gel for Acute Skin Wound Healing is listed as RECRUITING and has reported nothing. So the direction of the animal and cell evidence is consistent, and the size of any effect in a person is unmeasured.

Question 6

What does copper tripeptide-1 do?

Accepted Answer

Three effects recur across this literature, and all three were measured in cells, animals or skin samples. The first is building structure. A 2018 review reports that GHK stimulates blood vessel and nerve outgrowth, increases collagen, elastin, and glycosaminoglycan synthesis, as well as supports the function of dermal fibroblasts. The second is slowing breakdown. A 2023 liposome study found that the GHK-Cu did not significantly affect the tyrosinase activity but led to 48.90 ± 2.50% elastase inhibition, thus reducing the rate of elastin degeneration. Elastase is the enzyme that breaks down elastin, which is the protein letting skin spring back. The third is damping inflammation. A 2026 study of a GHK-Cu complex reports that it suppressed the transcription of key Th2 cytokines (IL-4, IL-5, IL-10, and IL-13) in a skin cell model of eczema. A 2025 review names the cosmetic end of this plainly, crediting the molecule with reducing fine lines and wrinkles, tightening skin, improving its elasticity, etc.

Question 7

Has GHK-Cu been given to people?

Accepted Answer

Once, in a registered trial that has not reported, and everything else in the human record is measurement rather than treatment. The trial is Topical GHK-Cu Gel for Acute Skin Wound Healing, a Phase 2 study marked RECRUITING with no published result. What exists instead is human measurement of the body's own GHK. A 2023 asthma study found that the plasma GHK levels of patients with asthma were significantly lower than those of age-matched healthy controls. It also reports that in asthma patients, plasma GHK levels display a moderate correlation with FEF25-75%, which is a measure of how freely air moves through the smaller airways. Those are observations in patients who were given nothing, in which blood was drawn and compared and nobody received GHK-Cu, so a correlation between a low level and a disease does not tell you that raising the level changes the disease. That is the experiment none of the studies in this record ran in people.

Question 8

What happens to GHK levels as you get older?

Accepted Answer

They fall with age, and the numbers are specific. A 2020 paper reports GHK as a naturally occurring peptide found in human serum with levels averaging 200 ng/ml at age 20 but declining to an average of 80 ng/ml by age 60, which is roughly a sixty per cent reduction across forty years of adult life. Illness tracks in the same direction. In a 2023 asthma study, patients with FAO had significantly lower GHK levels, FAO standing for fixed airflow obstruction, the component of asthma that an inhaler does not open up. Here is the limit on all of it. Every one of these numbers is an association read off a blood sample at a single moment, in people who were receiving nothing at the time. A concentration that declines with age or with illness does not tell you that putting more of it back restores anything, and no study among the research behind this page has given GHK-Cu to a person and then re-measured either the circulating level or whatever it was supposed to change.

Question 9

Does GHK mess with hormones?

Accepted Answer

No study among the research behind this page has measured testosterone, oestrogen, thyroid or any other hormone in a person given GHK-Cu. The nearest findings are about signalling molecules rather than hormones. A 2023 study reports that GHK-Cu decreased TGF-β1 level by increasing SIRT1 expression and activating SIRT1 deacetylation in airway epithelial cells, from the validation data of experiments in vivo and vitro. TGF-β1 is a growth factor, and SIRT1 is an enzyme that switches other proteins on and off. Neither is an endocrine hormone, and neither was measured in a person taking anything. A 2024 skin-delivery study lands in the same territory, reporting that its copper peptide system mainly regulates Nrf2, SIRT1, and PEG2/COX-2-related signaling pathways. Those are stress and inflammation controls rather than endocrine ones. So the compound does touch signalling systems, and no study among the research behind this page has looked at the hormonal ones. The absence of a finding here is an absence of measurement rather than a measurement of absence.

Question 10

Does GHK-Cu do anything for muscle?

Accepted Answer

One study says yes, in mice, and it is worth reading closely because it also carries a human measurement. The 2023 study looked at muscle wasting in chronic obstructive pulmonary disease, and it began with blood. Plasma GHK levels were decreased in patients with COPD (70.27 ± 38.87 ng/mL vs. 133.0 ± 54.54 ng/mL, P = 0.009), in nine patients against eleven healthy controls. Those levels were associated with pectoralis muscle area, which is the size of the chest muscle. Then it tested the compound: GHK-Cu was found to rescue CSE-induced skeletal muscle dysfunction in C2C12 myotubes, which are muscle cells grown in a dish. In mice, GHK-Cu treatment (0.2 and 2 mg/kg) reduces CS-induced muscle mass loss. The authors conclude that exogenous administration of glycyl-l-histidyl-l-lysine-Cu2+ could protect against cigarette smoking-induced skeletal muscle dysfunction via sirtuin 1. Read the model carefully, because these were mice losing muscle to cigarette smoke, and the compound limited that loss. Limiting a specific injury in mice is a different question from adding muscle to a healthy person, and the second has not been asked.

Question 11

Does GHK-Cu do anything for the brain?

Accepted Answer

In mice the effect is measurable, and in people it has not been studied at all. A 2024 study ran the most direct test. Male and female 5xFAD transgenic mice on the C57BL/6J background at 4 months of age were given 15 mg/kg GHK-Cu intranasally 3 times per week for 3 months until 7 months of age. Those are mice engineered to grow Alzheimer's-type plaques, dosed up the nose for twelve weeks. The result was clear in that model, where in those mice, intranasal GHK-Cu treatment delayed cognitive impairment, reduced amyloid plaques, and lowered MCP1-mediated inflammation levels in the frontal cortex and hippocampus. A 2012 review had already proposed GHK tripeptide as a possible therapeutic agent against age-associated neurodegeneration and cognitive decline. Three things limit how far that travels. The dose was 15 mg/kg, far above anything applied to skin, and the route was intranasal, which is neither topical nor injected. The animals themselves were engineered to produce plaques on a schedule, so delaying that is not the same as protecting an ageing human brain.

Question 12

How long does it take for GHK-Cu to start working?

Accepted Answer

No study among the research behind this page has measured how long a person waits for a change they can see, so the durations on record all belong to the experiments rather than to the experience. The animal work ran for months: the mouse brain study dosed 3 times per week for 3 months, and read its results at the end of that window rather than along the way. Delivery studies measure an entirely different clock. A 2025 study of a GHK-Cu-loaded material reports that it exhibits sustained release properties for 7 days, and a 2023 liposome study measured how much peptide a carrier holds, choosing formulations with EE of 31.7 ± 0.9% and 20.0 ± 2.8%, where EE is encapsulation efficiency, the share of peptide that made it inside the carrier. None of those numbers is an onset, because they describe how long an experiment ran, or how long a material keeps releasing its contents, rather than how long a person waits for something to happen. That second number does not appear anywhere in the research behind this page.

Question 13

What are the negatives of GHK?

Accepted Answer

No study among the research behind this page has followed a person using GHK-Cu long enough to document what goes wrong, so the honest answer is an account of what has and has not been looked at. A 2026 sports medicine review covering unapproved peptides as a group reports that rigorous human safety data are scarce, and there is potential for serious harm to patients. A 2026 ageing review adds that these compounds lack long-term safety data and systematic validation. One narrow human observation does exist: in a 2015 microneedle study, no obvious signs of skin irritation were observed with the use of GHK-Cu after microneedle pretreatment, over nine hours on human skin. The copper is the part that is least characterised, because a 2025 review describes GHK-Cu as a fairly hydrophilic compound with limited permeation through the lipophilic stratum corneum, so how much copper actually crosses depends on the formulation rather than on the ingredient name. Nine hours on skin is not the same as repeated dosing over months. Documented reactions, interactions, daily use and who was excluded from these studies are each answered on the GHK-Cu safety page.

Question 14

How does GHK-Cu work?

Accepted Answer

Two accounts run through this literature, and they fit together rather than compete. The first is that GHK-Cu changes which genes are active. A 2018 review credits recent genetic data with revealing multiple biochemical pathways regulated by GHK. A 2023 study gives one concrete route, reporting that GHK-Cu decreased TGF-β1 level by increasing SIRT1 expression in airway epithelial cells, in vivo and vitro, with SIRT1 being an enzyme that silences and activates other proteins. The second account is simpler. GHK-Cu is a way of carrying copper. A 2026 study built on exactly that, using GHK-Cu as a stable copper source to provide a sustained release of Cu ions for cellular uptake. It points out that copper-dependent proteins (such as lysyl oxidase, LOX) require copper acquisition within the Golgi apparatus to achieve enzymatic activation. Lysyl oxidase is the enzyme that cross-links collagen, which is what lets connective tissue hold together. The second account explains why so much of the measured effect is structural. It also explains why delivery dominates this field: a 2025 review notes that the transport of liposomes containing GHK-Cu received little attention, and a copper carrier that does not arrive carries nothing.

GHK-Cu